- Ocular Therapeutix Inc (NASDAQ:OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have terminated the option and license agreement collaboration. The termination is effective immediately.
- The collaboration with Regeneron was initially formed in 2016 to develop and commercialize products containing Ocular’s sustained-release hydrogel technology in combination with Regeneron’s large molecule vascular endothelial growth factor for eye diseases.
- Under a 2020 amendment, the companies’ efforts have focused on R&D of an extended-delivery formulation of aflibercept to be delivered to the suprachoroidal space to treat retinal diseases.
- Price Action: OCUL shares traded 3.04% lower at $10.51 and on the last check Friday.
Walmart: Q2 Earnings Insights
Shares of Walmart (NYSE:WMT) fell 0.5% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share increased 14.10% over the past year to $1.78, which beat the estimate of $1.56.
